PDMR Dealing

RNS Number : 2105C
Oxford Biomedica PLC
07 October 2022
 

 

 

PDMR Dealing

 

Oxford, UK - 7 October 2022 : Oxford Biomedica plc ("Oxford Biomedica" or the "Company") (LSE:OXB), a leading gene and cell therapy group, was informed that Matthew Treagus, Chief Information Officer, has purchased 1,390 ordinary shares of 50p each ("Ordinary Shares") in the Company on 7 October 2022 on the London Stock Exchange at a price of 355.6655p. Following this purchase Matthew Treagus holds 5,891 Ordinary Shares representing 0.00006% of the Company.

 

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.

 

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")

a)

Name

Matthew Treagus

2.

Reason for the notification

a)

Position/status

Chief Information Officer

 

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 50 pence each

 

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Purchase

c)

Price(s) and volumes(s)

 

Price(s)

Volume(s)

£3.556655

1,390

d)

Aggregated information

· Aggregated volume

· Aggregated total

 

 

1,390

 

£4,943.75

 

e)

Date of the transaction

07-10-2022

f)

Place of the transaction

London Stock Exchange, Main Market (XLON)

 

 

 

-Ends-

 

For further information, please contact:


 

Oxford Biomedica plc:

Natalie Walter, Company Secretary

 

Tel: +44 (0)1865 783 000

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.

 

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector® platform, and is working on programmes from pre-clinical to commercial stage across a range of therapeutic areas with global partners.

 

Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In 2022, the Group established Oxford Biomedica Solutions, a US based subsidiary AAV manufacturing and innovation business, based near Boston, US.

 

Further information is available at www.oxb.com .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBKOBBDBDDAKK
UK 100